Philippine Cerebral Palsy Tue, 21 Jun 2022 15:51:33 +0000 en-US hourly 1 Philippine Cerebral Palsy 32 32 Pendella Technologies Offers Life and Disability Insurance Protection to Partners PEO Clients | New Tue, 21 Jun 2022 13:03:00 +0000

FORT MYERS, Fla., June 21, 2022 (GLOBE NEWSWIRE) — Pendella Technologies, a fast-growing technology company on a mission to eliminate bias in life insurance, will bring its life insurance platform and White-label disability insurance to more small-business employers through a new agreement with Colorado-based PEO Partners.

With Pendella’s AI-powered integrated technology, Partners PEO customers can now offer their employees the ability to easily compare, quote and purchase critical financial protection online in minutes, without the need for a medical examination.

The partnership expands Partners PEO’s current offerings for high-risk industries, which also include payroll, security, workers’ compensation, human resources and other benefits.

The Pendella platform provides access to a variety of affordable individual life and disability insurance coverage from leading national providers. Simplified underwriting gives everyone, regardless of age, health or income level, the ability to purchase individual life and disability insurance policies for a low monthly payment.

“Adding life and disability insurance protection from Pendella allows us to deliver on our promise to be a full-service partner for our customers. We know employers are looking for more ways to attract and retain talent and adding important benefits like these will bring great comfort to employees and their families,” said Darlene Suer, CEO of Partners PEO. .

Consumer awareness and demand for life insurance has peaked nationally in recent years due to the COVID-19 pandemic, according to the financial research firm LIMRA. Three in 10 Americans say they are more likely to buy coverage than they were a few years ago, according to a recent LIMRA survey, and policy sales are steadily rising. Whole life premium rose 27% in the fourth quarter of 2021, LIMRA said, the strongest quarterly premium growth in 30 years.

“I started Pendella to help close the life insurance protection gap by making it easier for people to get the coverage they need,” said Pendella Founder and CEO Bob Gaydos. “We’re looking for more forward-thinking PEOs like Partners to help us reach the more than 100 million Americans who don’t have adequate – or any – life insurance protection.”

About Pendella

Pendella is a technology company that exists to make individual life and disability insurance financial protection available to everyone, regardless of age, health status or income level. Pendella’s comprehensive enterprise SaaS solution is powered by artificial intelligence and big data to automate underwriting and deliver a simple, intuitive and enjoyable experience to thousands of people through partnerships with insurance companies and top-notch distributors. White-label customization allows for a seamless end-to-end experience. Instant life and disability insurance in minutes. No paperwork. No medical examinations. Implemented with minimal effort.

For more information or to schedule an interview, contact: [email protected]

A photo accompanying this ad is available at

Copyright 2022 GlobeNewswire, Inc.

Ex-dentist apologizes for not spotting tooth decay and botching treatment Mon, 09 May 2022 04:03:03 +0000 A dentist has been found to have breached the health and disability code, after failing to properly diagnose a dental injury on a patient. Stock / 123rf

A young woman whose dentist botched a procedure and failed to properly spot the tooth decay says she almost lost one of her teeth – if she hadn’t seen another dentist in time.

The woman suffered from a serious tooth injury, which previous x-rays should have been obvious to her dentist, the Assistant Commissioner for Health and Disability found.

But the potentially harmful lesion was only discovered when the patient visited a dentist abroad, who alerted her to the decay of not one but seven of her teeth.

According to the findings of Deputy Commissioner Dr Vannessa Caldwell, the patient started seeing the New Zealand dentist in 2011 as a teenager.

On the first visit, an X-ray was taken, with the dentist, whose name is suppressed, commenting that the patient’s teeth were “very well cared for”.

But the patient claims that the doctor did not raise the issue of early mineral loss – clearly visible on the x-ray.

There was no reference to mineral loss on the patient’s clinical notes of the visit.

The patient continued to be seen for annual checkups for the next two years. During a visit in 2013, the dentist noticed a lesion on a tooth, but there was no evidence in clinical notes that this had been discussed with the patient.

A year later, the patient returned to the office, with the dentist performing “restorative treatment” on the tooth.

In January 2015, a year after the restoration work, the patient contacted her dentist concerned about a dark spot on the tooth.

A week later, restoration work was again undertaken on two teeth – one of which was the same tooth that had been operated on 12 months previously.

The dentist said in his clinical notes that he “didn’t trust” his original work.

The patient consulted again in August 2015 and again in June 2016. No problems were reported and no advice was provided to the patient in the clinical notes.

The patient then moved abroad for three years, returning to the practice for a check-up in February 2019.

Two other lesions were identified, but the dentist advised the patient to return in six to nine months to reassess any corrective action.

During the same appointment, the patient expressed concern about her sore wisdom teeth, but the dentist told her they were fine.

The patient returned to the practice that same month for restorative work on one tooth, as well as another restoration on the same tooth which had now received three restorative works.

But the patient was worried about the advice she had received. Four months later, she visited another dentist while she was abroad.

The new dentist discovered several lesions on seven teeth, including one described as being so large that the patient was warned she was at risk of losing the entire tooth.

It was also discovered that the same wisdom teeth that the patient had complained about earlier had lesions. They were removed shortly thereafter.

In June 2020, when the patient visited another dentist, he recommended that the repair work undertaken on a tooth by her previous dentist be redone – the fourth time the treatment had to be repaired.

In total, the patient says she has attended more than 20 dental appointments since her last appointment with her original dentist in 2019.

In her investigation, the deputy commissioner found that the problems with the most badly damaged tooth should have been detected by the New Zealand dentist in 2019.

The dentist also failed to provide the patient with adequate information about the issues affecting her wisdom teeth.

The failure of both counts was a violation of the Code of Rights of Consumers of Health and Disability Services.

The dentist at the center of the complaint no longer practices and has already issued a formal apology for the harm caused to the patient.

Caldwell ordered the dentist to consider the patient’s impact statement and ordered him to undergo a competency exam if he ever returned to practice.

Causes, symptoms, treatment of cerebral hyperperfusion syndrome Fri, 15 Apr 2022 16:53:46 +0000

Cerebral hyperperfusion syndrome (CHS) is a rare but life-threatening risk of carotid endarterectomies and carotid artery stenting. These are surgical procedures that are used to increase blood flow in the carotid arteries, the main vessels that supply blood to the neck, brain and face.

CHS can cause swelling and bleeding in your brain. The death rate is as high as 50 percentand many who survive have permanent disabilities.

The term “CHS” is often used interchangeably with “reperfusion brain injury” or “reperfusion syndrome.” Read on to learn more about the causes of CHS and how it is managed.

Meaning of “hyperperfusion”

“Hyperperfusion” is the medical term for increased blood flow to an organ. The prefix “hyper” means increased or excessive, and “perfusion” refers to the passage of blood through a blood vessel.

Cerebral hyperperfusion is defined as an increase greater than 100% in blood flow in the carotid artery compared to baseline. Some people develop symptoms with an increase in blood flow as low as 20-40%.

CHS is a potential risk of carotid artery revascularization surgeries. These surgeries aim to increase blood flow in the carotid artery to prevent strokes in people with carotid artery disease. Blockages in the carotid arteries account for 15% of all strokes.

CHS was first discovered as a risk of a type of surgery called carotid endarterectomy, but it can also occur after stenting the carotid artery. It can develop immediately after surgery or up to a month later.

The exact reason why some people develop CHS remains unclear. Several factors are thought to contribute to this.

Loss of self-regulation

Normally, your brain regulates itself to maintain constant pressure when blood flow changes. Researchers believe that in some people with chronically low blood flow in the carotid artery, the brain may lose its ability to self-regulate and the blood vessels may remain chronically relaxed.

When blood flow increases after surgery, the brain may not constrict blood vessels appropriately to protect the beds of tiny blood vessels called capillaries.

Chronic high blood pressure

People with severe narrowing of the carotid artery often have high blood pressure. It is thought that high blood pressure that is already present may contribute to the development of CHS. Chronic high blood pressure can damage small blood vessels and lead to a breakdown of the blood-brain barrier.

Researchers found evidence of leakage of the protein albumin after breakdown of the blood-brain barrier in animal studies. This leakage can potentially activate a pathway that causes brain swelling and seizures.

Damage caused by nitric oxide and free radicals

Nitric oxide is a vasodilator, which means it relaxes blood vessels and lets more blood flow through.

It’s thought nitric oxide may contribute to autoregulatory and blood-brain barrier dysfunction in CHS. The buildup of harmful molecules called free radicals can damage brain tissue to 48 hours.

Dysfunction of baroreceptors

Baroreceptors are specialized receptors that sense blood pressure and send signals to your brain to up-regulate or down-regulate blood flow. During surgery, the nerves that carry information from these receptors can be damaged. This damage can lead to increased blood pressure that is difficult to control, even with medication. Fluctuations in blood pressure due to baroreceptor damage can last up to 12 weeks.

Most people with CHS have mild symptoms, but they can progress to severe and life-threatening symptoms if left untreated. The most common symptoms are:

Less common symptoms include:

This condition can be fatal in some cases.

CHS is a rare risk of carotid surgery. A study of 4,689 people undergoing carotid endarterectomy and 4,446 people undergoing carotid artery stenting found an incidence of 1.9% and 1.16%, respectively.

What can increase the risk of getting CHS?

Extensive studies have revealed that the three most common conditions associated with the development of CHS are:

  • more than 90% blockage of the carotid artery
  • severe blockages (or plaques) of blood vessels in the brain
  • long-standing pre-existing high blood pressure

Studies have also identified the following as risk factors for developing CHS after carotid surgery:

  • to be assigned female at birth
  • chronic kidney disease
  • left carotid disease
  • progressive neurological disorders
  • recurrent hemorrhaging (bleeding)
  • brain damage (tumors or damaged areas)
  • microvascular disease (disease of small blood vessels)
  • reduced ability of blood vessels in the brain to respond to changes in blood flow

What risks does CHS pose to your health?

If left untreated, CHS can lead to severe brain swelling, bleeding, permanent disability, or death.

A 2018 review of studies noted that 47% of CHS cases resulted in stroke, and more than half of strokes were fatal or disabling.

Treatment for CHS often includes intravenous drugs to lower blood pressure, such as labetalol and clonidine.

Antiepileptic drugs may be given to prevent seizures or to treat seizures if they occur.

Mannitol and hypertonic saline solution can be used to treat brain swelling. However, if these treatments are effective in the long term is not clear.

Surgery may be needed if bleeding occurs.

Taking steps to keep your blood pressure within a healthy range can help prevent CHS, as high blood pressure is considered a risk factor for its development.

Prompt identification and treatment of CHS is essential to prevent life-threatening complications. It is recommended that blood pressure be monitored by medical professionals continuously at least every 15 minutes for 24 hours or more after surgery.

Management of CHS focuses on reducing swelling, seizures, and bleeding, which are major causes of brain damage.

In the early stages, the swelling is usually reversible, but if it progresses to hemorrhage, the outlook is not as good. Until 30 percent people remain at least partially disabled and the mortality rate reaches 50%.

CHS is a rare risk of surgeries used to increase blood flow in the carotid artery. It is defined as an increase of more than 100% in blood flow in the carotid artery compared to baseline.

CHS can lead to serious complications such as permanent disability or death. Early recognition of CHS is key to receiving prompt treatment. Common early symptoms include headache, facial pain, or eye pain on one side. Seek immediate medical attention if you experience any of these symptoms within a month of carotid surgery.

]]> 0
Dystrogen Therapeutics’ Investigational DT-DEC01 Chimeric Cell Therapy for the Treatment of Duchene Muscular Dystrophy Shows Improvements in Safety and Functionality | DNA RNA and Cells Fri, 08 Apr 2022 09:06:48 +0000

Dystrogen Therapeutics’ Investigational DT-DEC01 Chimeric Cell Therapy for the Treatment of Duchene Muscular Dystrophy Shows Improvements in Safety and Functionality

  • Results continue to strengthen the safety and tolerability profile of DT-DEC01
  • The first review of functional outcomes in the low-dose cohort revealed improvements 3 months after administration of DT-DEC01
  • Therapy independent of the genetic mutation of the DMD patient, thus making DT-DEC01 a universal therapy for all DMD patients

MIAMI, FL, USA and WARSAW, Poland I April 7, 2022 I Dystrogen Therapeutics, Corp., the leader in chimeric cell therapies, today announced positive results from an ongoing study conducted in Poland under a hospital waiver protocol of DT-DEC01 (chimeric cells expressing the dystrophin (DEC)), the company’s experimental cell therapy for Duchenne muscular dystrophy (DMD). The results include functional and safety data over 1 to 3 months from three clinical trial participants in the low-dose cohort. During this period, no adverse events (AEs and SAEs) associated with DEC treatment were observed. DT-DEC01 is being developed for the treatment of DMD, a devastating neuromuscular disease associated with a lack of the protein dystrophin. DT-DEC01 is a modified chimeric cell that engrafts into skeletal and cardiac muscle, delivering a full-length dystrophin gene and related components of a healthy muscle cell, the absence of which is strongly associated with progressive degeneration and a shortened lifespan characteristic of the disease.

“There is currently no approved treatment for people with DMD that results in cure or significant reduction of the disease – a disease that causes significant disability in boys and young men and usually results in early mortality. It is very encouraging that we continue to see consistent results, positive data from our investigational cell therapy DT-DEC01 on multiple metrics, as we know the community needs more options,” said Maria Siemionow, MD Ph.D. ., Scientific Director of Dystrogen Therapeutics. “Improvements in functional measures at 1 and 3 months in participants of the low-dose cohorts who received DT-DEC01 are markedly different from what a matched natural history group according to age would predict with DMD. When combined with the strong and sustained expression of dystrophin results in preclinical studies and an encouraging safety profile seen to date, today’s results reinforce our confidence in DT-DEC01 and provide additional evidence supporting this approach as we move to the higher dose cohort in the next stage of clinical testing.

The Data and Safety Monitoring Board (DSMB) reviewed the data from the low dose clinical cohort (2 million DEC cells per kg) and issued a positive opinion on the safety of DT-DEC01 therapy. The DSMB recommends launching the 4M/kg cohort.

Cohort 1 (low dose):

Patient 02B. (7 year outpatient with Exon 3-12 deletion) 3 months post treatment showing improvement on a number of subjective and objective tests. Improvement in EMG (objective test) compared to baseline before treatment. Improved 6MWD, improved 10-meter walk/run time, grip strength and others. Increased number of steps via activity tracking.

Patient 03B. (Non-ambulatory age 15 with Exon 48-50 deletion) 2 months after treatment increased activity level from baseline. Improved grip strength, improved spirometry, improved upper limb strength.

Patient 04B. (outpatient 6-year-old child with nonsense mutation), 1 month after treatment, increase in number of steps via activity monitoring compared to baseline.

About DT-DEC01

DT-DEC01 is a chimeric cell therapy. The Advanced Therapeutic Drug (ATMP) is made using Dystrogen’s proprietary cell engineering technology that creates a DEC cell. Clinically, DEC cells have been shown to express CD56 at significantly higher levels than Duchenne patient myoblasts. DEC cells express favorable HLA characteristics that have multiple advantages. In preclinical studies, DEC cells have also been shown to express clinically significant levels of dystrophin compared to controls. DEC cell therapy has demonstrated significant functional improvement in cardiac, diaphragm, and other skeletal muscle strength and related function in preclinical trials. Because DEC therapy is designed to prevent an immune system response from being triggered, a major advantage of DEC therapy is that it does not require immunosuppression. The therapy is not associated with any genetic manipulation and therefore does not involve any risk of off-target mutation, does not use viral vectors and its use does not depend on the genetic mutation of the DMD patient, thus making DEC a therapy Universal for all DMD patients.

About Dystrogen Therapeutics Corp.

Dystrogen Therapeutics is a clinical-stage life sciences company engaged in the development of therapies for rare genetic diseases. The company was founded on the pioneering work of Professor Maria Siemionow, a world-renowned scientist and surgeon who led the team that performed the first near-total face transplant in the United States. Professor Siemionow’s research initially focused on creating chimeric cells that play a role in modulating the immune system’s response to a transplant. This led to the development of dystrophin-expressing chimeric cell therapy (DEC) which is designed to prevent the immune system from attacking chimeric cells. DECs are engineered cells and belong to a family of therapeutic technologies called Advanced Therapy Medicinal Products (ATMP). Using Dystrogen’s patented cell engineering technology, DECs are made by combining a defective cell from the Duchenne patient with a normal, functioning cell from a healthy donor. This new chimeric cell is composed of both donor and recipient cell structures, but resembles the patient’s immune system as its own cell and therefore does not trigger an immune response while it is functioning (i.e. that it produces dystrophin) like the patient’s normal cell. This offers a unique advantage and allows the patient’s body and immune system to accept the chimeric cell without rejection. In this way, Dystrogen has created dystrophin-producing cells that can be delivered intraosseously and then distributed systemically to be transplanted into the patient’s muscles (such as heart, diaphragm, skeletal muscles) and, as our research and related peer-reviewed publications demonstrate, increase their dystrophin levels. Increased dystrophin levels have been shown to correlate with improved functional outcomes, which has been confirmed in preclinical studies on DEC.

THE SOURCE: Therapeutic Dystrogen

]]> 0
Improving care for adults with intellectual and developmental disabilities Thu, 07 Apr 2022 11:07:43 +0000

In 2021, the American Academy of Neurology (AAN) announced the formation of a new group within the organization: the Adults with Intellectual and Developmental Disabilities (IDD) Section of the AAN. With the goal of providing resources and training to improve the care of children and adolescents with intellectual and developmental disabilities, the section is led by Seth M. Keller, MD.

Infants, children, and adolescents with DID often face comorbid conditions such as epilepsy, cerebral palsy, and autism, and are most often cared for by pediatric neurologists. Although, when these young people become adults and transition into adult neurology care, they often face challenges, as these neurologists have historically been ill-equipped and under-educated on how to care for them appropriately.

At the 2022 AAN Annual Meeting, April 2-7, in Seattle, Washington, NeurologyLive® sat down with Keller, a board-certified neurologist in private practice with Advocare Neurology of South Jersey, to discuss the needs of these patients and the goals of the section, whose leadership also includes Vice President Bhooma Aravamuthan, MD, DPhil.

NeurologyLive®: Could you provide information on the section for adults with intellectual and developmental disabilities at the AAN?

Seth M. Keller, MD: The section itself represents the population of adult patients with intellectual and developmental disabilities. For example, these would be people with autism, cerebral palsy and Down syndrome, who have suffered from a range of neurodevelopmental disorders since birth. Our section focuses on the issues that concern them as they move from the pediatric world to the adult world. Their types of complications, which are quite complex in this patient population, include epilepsy and various seizure disorders, but also movement disorders and spasticity. I focus not only on epilepsy myself, but on the aging population, those with the same type of condition, developmental disabilities, who are older adults. For example, one thing that is very, very prevalent in the developing population, particularly in people with Down syndrome, is early onset Alzheimer’s disease. For people with Down syndrome, it’s a really trying and difficult situation — 60% get Alzheimer’s disease before the age of 60. It is a real challenge and a tragedy when these difficulties arise in this population.

From your perspective in the field, as it relates to neurologists and clinicians, do you think the voice of the patient still needs more presence in the room?

Let me put it like this. When children have developmental disabilities, they are brought in with their advocate parents, who have a very strong and loud voice for their children. And so, in pediatrics and pediatric neurology, in particular, there’s often a lot of attention for developmental disabilities because the parents are front and center and because pediatrics has education and training, they have centers, you can get board certified in pediatrics for developmental disabilities. The challenge is that when they grow up, when they get to 18, they see adult providers—adult neurologists—and that’s basically where things hit the wall . This is because adult neurologists, essentially, receive no education or training in medical school, they receive no residency or fellowship training, in dealing with the neurological complications of adults with IDD. A lot of it really starts in the transition process, trying to find a supposedly good or competent adult neurologist who understands people with Down syndrome, understands people with cerebral palsy, who understands people with autism who develop neurological complications and trying to find an adult provider. It was very difficult. There have been articles written about this not only by the AAN, but also by other organizations like the Child Neurology Foundation, which are trying to help understand. The problem is that there is a lack of education and training for adult neurologists.

How is this transition process different for this patient population? Are there ongoing efforts to address these specific challenges?

There is not enough. I would like to admit that a lot is being done, but at this moment the creation of a section has arisen in this situation to be able to address these questions. One would be the complexity of seizures, and there would be a number of people who have syndromes. You and I were talking earlier about the different: Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex—to name a few—these different syndromes are essentially genetic. These genetic syndromes are not really appreciated or well known by adult neurologists.

The other complexity is that adult neurologists may not really value them as people of value or in need of equity in care. And that’s the other part about it. They may not be able—because they’re not really trained to see an adult with a developmental disability—to provide care. To treat someone—it’s a bit of a philosophical comment—and to treat a patient, you can of course know about a drug, you can know about a disease, you can order a test, but to really provide care to them, you have to be able, on some level, to connect with them as a person of value. And I’m not trying to throw anyone under the bus about this, but you really need to connect with them. There can be a disconnect between a neurologist or any other health care provider – not just neurology, really any health care provider – about connecting to someone who is not a small child, is not with his parent, someone you may not have the “warm and fuzzy” as much as possible with a child.

There are also many common behavioral issues. People may suffer from autism, seizures, or other types of common behavioral problems. The physician and neurologist may not have this level of comfort and be able to manage or cope with many behavioral issues concurrent with their neurological complication. The other aspect is that the caregivers sometimes may not be the mother and the father. There is a decent percentage of adults with developmental disabilities who may not be living with their mom and dad anymore. But if they are, they may be elderly parents or live in a group home, and the health care provider or neurologist may not be able to appreciate who the support provider who accompanies them. A direct support professional, who is this person? What are they doing? What is their decision regarding their ability to have a voice or a proxy for them or not?

Then try to get feedback and try to get information from patients, to whom you are not able to provide much information because they may be verbal or non-verbal badly. There are a number of complications that can make the neurologist uncomfortable, especially when he receives no education and training, and almost tries to deal with them as he would with someone else. one who does not have an intellectual disability when there are lots of difficulties or challenges that are different from normal and typical populations.

How are we going to settle this?

Education is part of it. There is a very important and valued nature for equity of care for diverse populations at AAN, and there is no other patient population that truly has so many equity and access challenges. quality services than adults with IDD. Right now we’re working very closely, which is a wonderful thing, with the AAN to sort out exactly that. In our chapter and with the leaders of our chapter, which is growing across the country and internationally, we try to be there as a voice. That’s why we are a chapter, we try to be there as a voice for adults with IDD, so we can make sure they have that voice talking about what it means to get an education and what it means to get trained. But how do we get it? In addition to our annual meeting, how can we get printed materials that neurologists, through their training, can learn from? Additionally, we truly, deeply appreciate the importance of advocacy, whether it’s a parent organization or an organization that supports various syndromes, like the Dravet Syndrome Foundation, the Lennox-Gastaut Foundation, or ‘others. We really appreciate that these foundations, these organizations are extremely important. I would say we really wouldn’t do much without helping with education and training without working with them in partnership on how we move forward. They live in there. They wake up, go to sleep every night and take care of these people while we go to see our next patient. So really, for us, we really have to make sure that everything we do is a discussion, talk to these various organizations and work with them at all levels.

Transcript edited for clarity. Click here for more AAN 2022 coverage.

]]> 0
Premera Blue Cross and Kinwell Medical Group Partner to Expand Access to Primary Care in Washington State Tue, 18 Jan 2022 17:01:01 +0000

Kinwell Medical Group’s new clinics exclusively serve Premera members; part of the health plan’s long-term strategy to address the primary care crisis

Mountlake Terrace, Wash., Jan. 18, 2022 (GLOBE NEWSWIRE) — Premera Blue Cross and Kinwell Medical Group today announced a collaboration to improve access to primary care in Washington. Kinwell Medical Group is opening primary care clinics across the state, which will exclusively serve people who have Premera Blue Cross, Premera Blue Cross Medicare, or LifeWise Health Plan of Washington plans as their primary insurance, as well as BlueCard holders.

This partnership is a key part of Premera’s strategy to address the growing crisis in primary care. By 2034, the United States is expected to face a shortage of up to 124,000 doctors, 48,000 of whom will be in primary care alone, according to a 2021 study by the Association of American Medical Colleges (AAMC).

While the study focuses primarily on future doctor shortages, Americans are now feeling the shortfall. According to a study conducted for the AAMC, 35% of people surveyed said they had trouble finding a doctor in the past two or three years. That’s 10 points higher than when the question was asked in 2015.

“If we are to live up to our mission to make health care work better, we simply cannot afford to sit idly by and let this crisis develop,” said Lee McGrath, vice-president. Executive Chairman of Healthcare Services for Premera. “That’s why Premera is working today to improve our members’ care experience and invest in educational programs focused on pipeline growth for future primary care providers.”

Kinwell Medical Group’s first two primary care clinics opened in December 2021 in Yakima and Wenatchee. Designed as integrated care centers, Kinwell Medical Group clinics provide on-site access to a variety of services. This will greatly improve customer service and reduce wait times for Premera members. Additional clinics will open across Washington this year.

“At Kinwell, we believe that alongside medical expertise, developing a true connection always makes a difference, and we are thrilled to provide this level of care to the Yakima and Wenatchee communities,” said Dr. Mia Wise. , president of Kinwell Medical. Group. “We want to provide personalized and sincere care by removing barriers for patients seeking to improve their health and create a real relationship with their healthcare team. We look forward to expanding our offering to communities across Washington State in the years to come. »

The collaboration with Kinwell Medical Group expands the concept first undertaken in Spokane. In 2019, Premera partnered with Vera Whole Health to open Vivacity Care Centers, which are primary care centers exclusive to its members. Today, there are four Vivacity Care Centers in Spokane County that provide Premera members with better access to primary care, an improved approach to their healthcare, and a better customer experience.

Investing in the Primary Care Pipeline

Although Premera is focused on the immediate need for access to affordable, quality care for its members, increasing the capacity of rural family medicine residencies remains important in long-term efforts to improve health care. for more than one million people living in rural Washington.

A 2017 study by the National Rural Health Association found that people living in rural areas have less access to primary and preventive care and are more likely to suffer from chronic disease, disability and premature death.

“If we don’t address the potential shortage of primary care providers now, rural communities will suffer the worst in the future,” McGrath said. “This will compound an already growing health equity problem. We need to invest in and develop educational programs that focus on both primary care and rural health care.

Since 2018, Premera has committed more than $58 million to improve access to care in rural areas. The company concentrates its investments in the following areas: recruitment and training of doctors, nurses and caregivers; clinical integration of behavioral health; programs to increase the capacity of mental health crisis centers in rural areas; and grants for small equipment to rural providers.

This included a recent $5.5 million grant to support Pacific Northwest University of Health Sciences (PNWU) rural family medicine educational pathway and training, which was developed in collaboration with MultiCare Health System, a leading organization non-profit health care. Premera also provided a $4.7 million grant to the University of Washington to establish the Rural Nursing Health Initiative to place current students in rural practices in Washington State.

Learn more about Premera investing in rural communities.

About Premera Blue Cross
Premera Blue Cross is a leading health plan in the Pacific Northwest, providing comprehensive health benefits and tailored services to more than 2.5 million people, from individuals to Fortune 100 companies. For more d information, visit

About Kinwell Medical Group
Launched in 2021, Kinwell Medical Group is an exclusive physician-owned network provider serving people who have Premera Blue Cross, Premera Blue Cross Medicare, or LifeWise Health Plan of Washington as their primary insurance, as well as BlueCard holders. Kinwell is changing the conversation about healthcare to include wellness and prevention. At Kinwell Clinics, care is provided by Kinwell Medical Group clinicians. They are supported by an independent company, Kinwell Physician Network, which provides administrative and commercial services allowing Kinwell Medical Group to focus on what it does best: caring for patients. For more information, visit

]]> 0
As COVID cases rise, RI’s disability insurance claims also rise Tue, 21 Dec 2021 22:43:46 +0000

PROVIDENCE, RI (WPRI) – As new cases of COVID-19 increase in Rhode Island – pushing more people into quarantine and out of work – so too are claims for temporary disability insurance.

Matt Weldon, director of RI’s labor and training department, said claims for TDI and temporary caregiver insurance have averaged 900 claims per week in recent months. But over the past month, those numbers have multiplied.

“Since November we’ve been climbing every week a bit at a time,” Weldon said. “Last week we had around 1,600 complaints. “

“It’s pretty busy right now,” he added.

According to DLT data, there were 1,450 new TDI and TCI claims the week ending December 4, 1,593 the week ending December 11, and 1,626 last week. Weldon said the increase in claims reflects the surge in coronavirus cases and the end of federal unemployment benefits.

Typically, TDI benefits represent about 60% of an individual’s income up to a cap of just under $ 1,000 per week. TDI services are not taxable, while TCI services are.

“We had the Pandemic Unemployment Assistance Program that was created by the federal government to provide unemployment benefits to people affected by COVID,” Weldon said. “It expired that first weekend in September.

“Since then, people who have been directly affected by COVID – that is to say they have COVID or they have to quarantine themselves – have not been eligible for unemployment,” he said. he adds. “So people applied for the TDI. “

This is the case of Katherin Ciociola. She contacted 12 responses on with a question after seeing that the TDI app requires “that you be physically examined by a qualified health care provider,” according to the online complaints portal.

“On the app, it asks you for information about the doctor,” said Ciociola, who has recently started to feel sick and is expected to be tested on Tuesday. “If you just go to a test site, you wouldn’t have this.”

Ciociola works from home, so her income would likely not be affected. But her boyfriend doesn’t have that option, and with two children, she worries about the impact on their income if he gets sick or has to stay home and take time off from work.

“If he needs to isolate or quarantine, how are we going to pay our bills, buy food for our family,” she said. “We’re just trying to plan ahead.”

Earlier in the pandemic, former governor Gina Raimondo signed an executive decree that waived the doctor’s note requirement, but has since expired. Weldon said that for the first week of benefits, however, the claimant does not need to provide medical certification.

“All they need is some sort of documentation, ie an email from the Department of Health or a test result,” Weldon said. “We would accept that.”

Right now, a doctor’s note would be required after the first week of benefits, but Weldon said he would soon extend it to two weeks as health officials recommend people quarantine themselves for 10 days when they test positive.

Tim white ([email protected]) is the Editor-in-Chief of Target 12 and Chief Investigative Journalist at 12 News, and the host of Newsmakers. Connect with him on Twitter and Facebook.

]]> 0
12 years of unwavering care for a son: actress Sabitta shares what she learned from life | Lifestyle Health Fri, 03 Dec 2021 04:58:57 +0000

The International Day of Persons with Disabilities celebrated on December 3 each year aims to raise awareness about disability issues and mobilize support for the dignity and well-being of people with disabilities. Many people see disability as divine punishment for the sins of the previous birth and offer sympathy to the disabled. However, such an attitude causes immense pain to mothers of children with this condition. These mothers devote all of their time to caring for their “special children” and have moving experiences. Among them is Sabitta George, famous actress, model and singer, well known for her role of “Lalithamma” in the television series “Chakkapazham”.

Sabitta left a thriving profession abroad and returned to her home state of Kerala on a mission. It was not to become famous as a celebrity but to change people’s attitudes towards disability. She also urges healthcare professionals to adopt a caring attitude towards people with disabilities.

Sabitta talks about her own experiences. For 12 years, she cared for her son, who was born disabled due to medical negligence in the United States. The celebrity shares her story with Onmanorama.

Costly medical error

“My first delivery was to the United States. The day before the scheduled date, I realized that the amniotic fluid was leaking and we immediately went to the hospital. On admission, staff tried to induce pain. Considering my state of health at the time and the weight of the fetus, there was little chance for a normal delivery. However, in many foreign countries such as the United States, all options for a normal childbirth would be explored during the first pregnancy. Cesarean section is the last resort, ”recalls Sabitta.

Sabita, Max and Sacha

Even though the epidural injection was given, there was no sign of labor for 16 hours. But Sabitta felt that the fetus was becoming less active and that there were variations in its heart rate. She also saw the variation on the monitor and asked for the doctor’s attention. However, the midwife on duty ignored Sabitta’s request and inserted the fetal scalp electrode. In the process, the midwife made a mistake and cut the umbilical cord.

Sabitta began to bleed and the child’s life was in danger. Sabitta and her mother, herself a nurse, begged the midwife to call the doctor. However, again, the midwife did not listen to them and tried to hide her mistake.

“My baby struggled for almost three hours with the umbilical lifeline cut. Finally, our persistent requests brought in the doctor and the Cesarean was performed, ”explains Sabitta.

The newborn was almost dead and was placed on a ventilator. “The doctors only gave him three days of life because the internal organs were badly damaged. The functioning of the kidneys and heart has been affected. There was also clotting in the brain cells. The struggle during childbirth made my son a person with cerebral palsy, ”says Sabitta.

The baby lacked sight, speech and mobility.

Chella (C) with Sabitta and Max

From three days to 12 years old

After giving birth, Sabitta spent several days outside the ICU. “I had taken all the precautions during pregnancy, such as having nutritious food with all the vitamins to deliver a healthy baby. My son was indeed in good health until a few hours before his birth. But, after giving birth, he fought for life in intensive care, ”explains the mother.

As the doctors had predicted only three days of life for the infant, they suggested that Sabitta remove him from the ventilator afterwards. However, she refused. “We decided to keep him on a ventilator for a week. On the sixth day, two drops of urine containing blood were detected and the baby was taken to the NICU. Finally, after spending four months there, the baby came back to life. The baby named Maxwell – Max for short – then lived for 12 years with Sabitta.

Sabitta’s appeal to mothers and health professionals

Many people trivialize work by citing cases of delivery on the side of the road and in homes. However, this is a very critical process, says Sabitta.

“I tell surrogates to respond whenever they feel the baby in their womb is not doing well. What mothers feel is more often than not true. Others may not take them seriously, but mothers should strongly demand that the child’s condition be examined by health professionals, ”she said.

Sabitta also wants healthcare professionals to change their attitude. “Medicine requires the extreme involvement of those who work in the field. People in the industry need to show compassion and empathy, ”says Sabitta.

Support system in the United States

Sabitta was fortunate to have a good support system for people with disabilities in the United States. “Disability is not seen as a punishment for past life sins in the United States. People also don’t watch disabled children and mothers there, ”she said.

“Max had a pleasant face. I believe it was a gift from God. His birth was the happiest and saddest event of my life, ”says the mother.

“These children teach us a lot. I learned of Max’s patience and compassion. It took an hour to give her 10 drops of liquid food. Any rush could cause him to choke on the food. When he was two years old, a tube was inserted to feed Max. He was fed by the tube until his death, ”recalls Sabitta.

Only liquid food could be given to Max. Because his kidneys were damaged, Max took only skim milk, watermelon juice and grape juice.

Five years after Max was born, he had a sister, Sasha. To avoid Max’s fate, she was delivered by Caesarean section at eight months. “Sasha loved Max. I could devote all my time to Max because Sasha also sacrificed a lot. When I spent all the time with Max in the hospital and at home during his last days on a ventilator, Sasha m “Said not to worry about her and take care of her brother. Her words gave me a lot of courage and support,” says Sabitta.

An angel named Chella

To take care of Max, Sabitta was helped by Chella, a Mexican woman. “She had a very long name but we called her Chella. She didn’t speak English and I didn’t know Spanish. We still took good care of Max. I learned from Chella that language or nationality was not a barrier to helping others during a crisis, ”said the celebrity.

“When God challenges us a great deal, an angel is also sent for our help. I realized this truth thanks to Chella, ”reveals Sabitta.

Chella (R) and Max

Normal schooling

Children with disabilities should not be confined to their homes, says Sabitta. “Max studied at a normal school in the United States because the facilities there are extremely suitable for people with disabilities. In addition to a specialized classroom, school buses have ramps, ”she emphasizes.

At school, Max was fed by an assistant named Miss Hedda. “She was a good companion for Max. The curriculum in the United States also emphasizes caring for people with disabilities. The company is also very considerate without being sympathetic. It’s an atmosphere suitable for people with disabilities, ”explains Sabitta.

Max Home Foundation

“Training to integrate children with disabilities into the mainstream should start at an early age. Changes are needed in the education system for this. Other children should be familiar with the needs of their disabled peers. Max was taken to schools where I worked as a volunteer and the students read him stories. Although he couldn’t hear or see them, Max made it possible for other children to understand and accept people with disabilities, ”says Sabitta.

In order to carry out her disability support projects, Sabitta registered a foundation called “Max Home” in the United States. As part of this project, medical supplies are being distributed to disabled people in Kerala. “We never donate money, but our volunteers identify the special need and provide items such as specialized wheelchairs, water beds, breathing apparatus and hearing aids,” she says.

The funds for the foundation are provided by Sabitta from her savings and with the support of friends. “We do not conduct any fundraising campaign. Our activities are shared on a “Max Home” Facebook page, ”she says.

]]> 0